Table 7. Significantly impacted pathways in human prostate cancer as determined by SPIA.
| Name | NDE/pSize | pNDE | pPERT | pG | pGFdr |
|---|---|---|---|---|---|
| Proteoglycans in cancer | 140/201 | 1.75E-05 | 5.00E-06 | 2.11E-09 | 1.86E-07 |
| Hippo signaling pathway | 112/153 | 3.12E-06 | 1.60E-02 | 8.90E-07 | 3.91E-05 |
| Pathways in cancer | 257/398 | 7.77E-05 | 2.00E-03 | 2.59E-06 | 7.60E-05 |
| Focal adhesion | 144/207 | 1.48E-05 | 2.10E-02 | 4.97E-06 | 1.09E-04 |
| cGMP-PKG signaling pathway | 118/167 | 2.80E-05 | 3.07E-01 | 1.09E-04 | 1.92E-03 |
| Calcium signaling pathway | 115/180 | 1.08E-02 | 4.00E-03 | 4.78E-04 | 7.01E-03 |
| Ras signaling pathway | 144/225 | 4.36E-03 | 2.90E-02 | 1.26E-03 | 1.59E-02 |
| TGF-β signaling pathway | 60/80 | 1.95E-04 | 8.54E-01 | 1.62E-03 | 1.78E-02 |
| Chronic myeloid leukemia | 55/73 | 2.93E-04 | 8.74E-01 | 2.37E-03 | 2.32E-02 |
| Basal cell carcinoma | 36/55 | 8.03E-02 | 6.00E-03 | 4.16E-03 | 3.59E-02 |
| Regulation of actin cytoskeleton | 135/213 | 9.11E-03 | 6.80E-02 | 5.20E-03 | 3.59E-02 |
| ErbB signaling pathway | 60/87 | 5.98E-03 | 1.07E-01 | 5.34E-03 | 3.59E-02 |
| Glioma | 48/65 | 1.50E-03 | 4.51E-01 | 5.60E-03 | 3.59E-02 |
| Small cell lung cancer | 58/86 | 1.38E-02 | 5.00E-02 | 5.71E-03 | 3.59E-02 |
| Oxytocin signaling pathway | 105/157 | 1.82E-03 | 4.53E-01 | 6.69E-03 | 3.87E-02 |
| MAPK signaling pathway | 152/254 | 7.51E-02 | 1.30E-02 | 7.75E-03 | 3.87E-02 |
| Cell cycle | 85/124 | 1.60E-03 | 6.41E-01 | 8.07E-03 | 3.87E-02 |
| MicroRNAs in cancer | 97/149 | 8.72E-03 | NA | 8.72E-03 | 3.87E-02 |
| cAMP signaling pathway | 132/200 | 1.15E-03 | 9.75E-01 | 8.76E-03 | 3.87E-02 |
| Rap1 signaling pathway | 130/211 | 3.42E-02 | 3.30E-02 | 8.80E-03 | 3.87E-02 |
NDE = number of differentially expressed elements, pSize = pathway size, pNDE = overrepresentation probability, pPERT = perturbation probability, pG = global probability, pGFdr = false discovery rate-adjusted global probability. Bold pathways were also significant by Gene Set Enrichment Analysis.